Operating Lease, Right-of-Use Asset of ALNYLAM PHARMACEUTICALS, INC. from 01 Jan 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
ALNYLAM PHARMACEUTICALS, INC. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 01 Jan 2019 to 30 Sep 2025.
  • ALNYLAM PHARMACEUTICALS, INC. Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $191,390,000, a 2.6% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

ALNYLAM PHARMACEUTICALS, INC. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $191,390,000 -$5,018,000 -2.6% 30 Sep 2025 10-Q 30 Oct 2025 2025 Q3
Q2 2025 $192,401,000 -$5,902,000 -3% 30 Jun 2025 10-Q 31 Jul 2025 2025 Q2
Q1 2025 $197,233,000 +$1,765,000 +0.9% 31 Mar 2025 10-Q 01 May 2025 2025 Q1
Q4 2024 $191,148,000 -$8,584,000 -4.3% 31 Dec 2024 10-Q 30 Oct 2025 2025 Q3
Q3 2024 $196,408,000 -$7,077,000 -3.5% 30 Sep 2024 10-Q 31 Oct 2024 2024 Q3
Q2 2024 $198,303,000 -$10,498,000 -5% 30 Jun 2024 10-Q 01 Aug 2024 2024 Q2
Q1 2024 $195,468,000 -$19,581,000 -9.1% 31 Mar 2024 10-Q 02 May 2024 2024 Q1
Q4 2023 $199,732,000 -$15,404,000 -7.2% 31 Dec 2023 10-K 13 Feb 2025 2024 FY
Q3 2023 $203,485,000 -$15,317,000 -7% 30 Sep 2023 10-Q 02 Nov 2023 2023 Q3
Q2 2023 $208,801,000 -$15,120,000 -6.8% 30 Jun 2023 10-Q 03 Aug 2023 2023 Q2
Q1 2023 $215,049,000 -$13,720,000 -6% 31 Mar 2023 10-Q 04 May 2023 2023 Q1
Q4 2022 $215,136,000 -$16,539,000 -7.1% 31 Dec 2022 10-K 15 Feb 2024 2023 FY
Q3 2022 $218,802,000 -$17,051,000 -7.2% 30 Sep 2022 10-Q 27 Oct 2022 2022 Q3
Q2 2022 $223,921,000 -$14,168,000 -6% 30 Jun 2022 10-Q 28 Jul 2022 2022 Q2
Q1 2022 $228,769,000 -$8,444,000 -3.6% 31 Mar 2022 10-Q 28 Apr 2022 2022 Q1
Q4 2021 $231,675,000 -$9,810,000 -4.1% 31 Dec 2021 10-K 23 Feb 2023 2022 FY
Q3 2021 $235,853,000 -$9,381,000 -3.8% 30 Sep 2021 10-Q 28 Oct 2021 2021 Q3
Q2 2021 $238,089,000 +$8,415,000 +3.7% 30 Jun 2021 10-Q 03 Aug 2021 2021 Q2
Q1 2021 $237,213,000 +$15,933,000 +7.2% 31 Mar 2021 10-Q 29 Apr 2021 2021 Q1
Q4 2020 $241,485,000 +$20,288,000 +9.2% 31 Dec 2020 10-K 10 Feb 2022 2021 FY
Q3 2020 $245,234,000 +$21,790,000 +9.8% 30 Sep 2020 10-Q 05 Nov 2020 2020 Q3
Q2 2020 $229,674,000 +$3,317,000 +1.5% 30 Jun 2020 10-Q 06 Aug 2020 2020 Q2
Q1 2020 $221,280,000 -$5,132,000 -2.3% 31 Mar 2020 10-Q 06 May 2020 2020 Q1
Q4 2019 $221,197,000 -$8,803,000 -3.8% 31 Dec 2019 10-K 11 Feb 2021 2020 FY
Q3 2019 $223,444,000 30 Sep 2019 10-Q 31 Oct 2019 2019 Q3
Q2 2019 $226,357,000 30 Jun 2019 10-Q 06 Aug 2019 2019 Q2
Q1 2019 $226,412,000 31 Mar 2019 10-Q 02 May 2019 2019 Q1
Q4 2018 $230,000,000 01 Jan 2019 10-Q 31 Oct 2019 2019 Q3
* An asterisk sign (*) next to the value indicates that the value is likely invalid.